SAVA News - Candlesense

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments f...

Investor

3 days ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments f...

What is the expected impact of the announced business update on the company’s competitive positioning within the CNS therapeutic market? Are there any risks highlighted in the update that could affect the company’s valuation or credit facilities? What is the market’s perception of Cassava’s long‑term growth prospects based on this release?

Earnings

14 days ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigation...

Is there any indication that this change will affect the company's cash burn rate or upcoming financing needs? What are the potential short‑term price movements versus long‑term valuation implications of this news? Could this appointment influence analyst coverage or consensus estimates for SAVA stock?

Leadership

21 days ago